trending Market Intelligence /marketintelligence/en/news-insights/trending/1aFmhUIGNUZkNI5FA26e8A2 content esgSubNav
In This List

Alimera Sciences names CEO, CFO under succession plan


Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Alimera Sciences names CEO, CFO under succession plan

Alimera Sciences Inc. promoted Richard Eiswirth Jr., who is also a president of the company, from CFO to CEO and named him to the board.

The executive change was made following the approval of a succession plan by Alimera's board that is intended to be effective Jan. 2.

Under the succession plan, C. Daniel Myers, co-founder of the company, retired as CEO and became a consultant to Alimera and nonexecutive board chairman.

Moreover, J. Philip Jones, the company's former vice president of finance, was appointed as CFO.

Philip Ashman, who was previously Alimera's senior vice president managing director Europe, was named as COO and senior vice president commercial operations Europe.

Alpharetta, Ga.-based Alimera Sciences is a pharmaceutical company, which engages in the research, development and commercialization of prescription ophthalmic, or eye-related, pharmaceuticals.